The Pathology Core of the Mayo Clinic Cancer Center SPORE in Brain Cancer will provide a coordinated and centralized resource dedicated to procurement and processing of tissues obtained from patients with gliomas. The Goal of the Pathology Core is to procure tissue and specimens from nearly every newly diagnosed or relapsed glioma patient seen at the Mayo Clinic and from all patients entered onto SPORE protocols. The Pathology Core will coordinate acquisition of both normal and neoplastic brain tissues for translational research and ensure appropriate diagnosis and quality of tissue. A portion of normal and tumoral brain tissue from each patient will be obtained fresh, processed for culture/xenograft and/or stored frozen to provide investigators with DNA and RNA. The remainder of the tissue will be available in paraffin blocks stored at the Mayo Clinic Tissue Registry. Oversight will be by the Administrative Core and its Executive Committee. The Pathology Core will also serve as a resource of expertise, collaborative effort and service for the pathology needs of the individual projects. The Core will interface with and be electronically integrated with the Neuro-Oncology Database and the Biostatistics Core to provide investigators with clinically annotated tissues. The collection, banking, and use of tissue will be performed with appropriate patient consent and institutional approval. The Pathology Core will interact and collaborate with other Brain Tumor SPOREs to promote resource sharing, and integrate scientific projects of mutual interest.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA108961-03
Application #
7285253
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2006-09-01
Budget End
2007-08-31
Support Year
3
Fiscal Year
2006
Total Cost
$126,753
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Jung, Mi-Yeon; Kang, Jeong-Han; Hernandez, Danielle M et al. (2018) Fatty acid synthase is required for profibrotic TGF-? signaling. FASEB J 32:3803-3815
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Zhou, Dan; Alver, Bonnie M; Li, Shuang et al. (2018) Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues. Genome Biol 19:43
Vaubel, Rachael A; Caron, Alissa A; Yamada, Seiji et al. (2018) Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Brain Pathol 28:172-182
Chen, Xiaoyue; Zhang, Minjie; Gan, Haiyun et al. (2018) A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun 9:2949
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Chen, Jee-Wei E; Pedron, Sara; Shyu, Peter et al. (2018) Influence of Hyaluronic Acid Transitions in Tumor Microenvironment on Glioblastoma Malignancy and Invasive Behavior. Front Mater 5:
Youland, Ryan S; Pafundi, Deanna H; Brinkmann, Debra H et al. (2018) Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. J Neurooncol 137:583-591
Stathias, Vasileios; Jermakowicz, Anna M; Maloof, Marie E et al. (2018) Drug and disease signature integration identifies synergistic combinations in glioblastoma. Nat Commun 9:5315
Huff, Amanda L; Wongthida, Phonphimon; Kottke, Timothy et al. (2018) APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Mol Ther Oncolytics 11:1-13

Showing the most recent 10 out of 254 publications